The stock of Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) has increased by 6.35 when compared to last closing price of 17.00. Despite this, the company has experienced a 13.07% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-12 that BOSTON and LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Is It Worth Investing in Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Right Now?
The 36-month beta value for CNTA is at 1.50. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CNTA is 79.98M, and currently, shorts hold a 2.68% of that float. The average trading volume for CNTA on November 14, 2024 was 626.83K shares.
CNTA’s Market Performance
CNTA’s stock has seen a 13.07% increase for the week, with a 12.37% rise in the past month and a 38.12% gain in the past quarter. The volatility ratio for the week is 5.60%, and the volatility levels for the past 30 days are at 4.74% for Centessa Pharmaceuticals plc ADR The simple moving average for the last 20 days is 13.59% for CNTA stock, with a simple moving average of 56.05% for the last 200 days.
Analysts’ Opinion of CNTA
Many brokerage firms have already submitted their reports for CNTA stocks, with Morgan Stanley repeating the rating for CNTA by listing it as a “Overweight.” The predicted price for CNTA in the upcoming period, according to Morgan Stanley is $26 based on the research report published on September 20, 2024 of the current year 2024.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CNTA reach a price target of $33. The rating they have provided for CNTA stocks is “Buy” according to the report published on September 19th, 2024.
Oppenheimer gave a rating of “Outperform” to CNTA, setting the target price at $14 in the report published on July 18th of the current year.
CNTA Trading at 14.37% from the 50-Day Moving Average
After a stumble in the market that brought CNTA to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.63% of gains for the given period.
Volatility was left at 4.74%, however, over the last 30 days, the volatility rate increased by 5.60%, as shares surge +10.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.58% upper at present.
During the last 5 trading sessions, CNTA rose by +13.07%, which changed the moving average for the period of 200-days by +118.62% in comparison to the 20-day moving average, which settled at $15.92. In addition, Centessa Pharmaceuticals plc ADR saw 127.14% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTA starting from SAHA SAURABH, who proposed sale 32,023 shares at the price of $18.28 back on Nov 13 ’24. After this action, SAHA SAURABH now owns shares of Centessa Pharmaceuticals plc ADR, valued at $585,418 using the latest closing price.
Weinhoff Gregory M, the Chief Business Officer of Centessa Pharmaceuticals plc ADR, sale 11,742 shares at $15.38 during a trade that took place back on Oct 25 ’24, which means that Weinhoff Gregory M is holding 183,266 shares at $180,628 based on the most recent closing price.
Stock Fundamentals for CNTA
Current profitability levels for the company are sitting at:
- -23.43 for the present operating margin
- 0.9 for the gross margin
The net margin for Centessa Pharmaceuticals plc ADR stands at -23.37. The total capital return value is set at -0.28. Equity return is now at value -42.73, with -32.83 for asset returns.
Based on Centessa Pharmaceuticals plc ADR (CNTA), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -1.55. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -31.96.
Currently, EBITDA for the company is -166.07 million with net debt to EBITDA at 2.01. When we switch over and look at the enterprise to sales, we see a ratio of 233.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.52.
Conclusion
In conclusion, Centessa Pharmaceuticals plc ADR (CNTA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
